Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction

H.M. Furtado, Remo; P. Bonaca, Marc; Raz, Itamar; A. Zelniker, Thomas; Mosenzon, Ofri; Cahn, Avivit; Kuder, Julia; A. Murphy, Sabina; L. Bhatt, Deepak; A. Leiter, Lawrence; K. McGuire, Darren; Wilding, John; T. Ruff, Christian; Carlos Nicolau, José; Gause‐Nilsson, Ingrid; Fredriksson, Martin; Maria Langkilde, Anna; S. Sabatine, Marc; D. Wiviott, Stephen

doi:10.1161/circulationaha.119.039996

Public

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction

Published in Circulation • Mar 18, 2019

Authors:

Remo H.M. Furtado

Marc P. Bonaca

Itamar Raz

Abstract

BACKGROUND: Sodium glucose transporter-2 inhibitors reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history of atherosclerotic cardiovascular disease. Because of their baseline risk, patients with previous myocardial infarction (MI) may d...

Subject

Medicine

Dapagliflozin

Myocardial infarction

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!